Back to search

Article

HLA-mismatched micro-transplantation as post-remission treatment compared to autologous hematopoietic stem cell transplantation or consolidation with single agent cytarabine for favorable or intermediate risk acute myeloid leukemia

2022-05-27

Abstract excerpt

There was some heterogenity in low or intermediate risk acute myeloid leukemia (AML) stratified by European LeukemiaNet (ELN), the optimal post-remission treatment for an individual favorable and intermediate risk genetics AML patient has not yet been established. HLA-mismatched stem cell micro-transplantation (MST), a novel apporoach of transplantation, which may improve outcomes and avoid graft versus host disea...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7973bda3-cdf5-572b-9c41-86fcc61a4b23
DOI
10.21203/rs.3.rs-1664364/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
HLA-mismatched micro-transplantation as post-remission treatment compared to autologous hematopoietic stem cell transplantation or consolidation with single agent cytarabine for favorable or intermediate risk acute myeloid leukemiaDOI 10.21203/rs.3.rs-1664364/v1
Unmanipulated haploidentical hematopoietic stem cell transplantation for mixed phenotype acute leukemia: a single center studySemantic proximity
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.Semantic proximity
[Analysis of the clinical characteristics of acute myeloid leukemia related to the treatment of hematological and solid tumors].Semantic proximity
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.Semantic proximity
Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: A study from the Acute Leukemia Working Party of the EBMTSemantic proximity
Similar Outcome With Haploidentical, Matched Sibling, or Matched Unrelated Donor Hematopoietic Cell Transplantation for Adult Patients With Adverse-Risk TP53-Mutated Acute Myeloid Leukemia in First Remission: A Comparative Study From the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.Semantic proximity
Comparison of Allogeneic Transplant Outcomes Between Matched Sibling Donors and Alternative Donors in Patients Over 50 Years of Age with Acute Myeloid Leukemia: 8/8 Allele-Matched Unrelated Donors and Unrelated Cord Blood Provide Better Leukemia-Free Survival Compared with Matched Sibling Donors During Nonremission Status.Semantic proximity
Stem Cells Micro-transplantation in Elderly Patients Aged Over 70 With Acute Myeloid Leukemia: a Multicenter, Prospective, Non-interventional StudySemantic proximity
Safety and efficacy of venetoclax-azacitidine combined with low-dose idarubicin and cytarabine regimens for the treatment of newly diagnosed acute myeloid leukemia patients compared to the standard chemotherapy: a propensity score-matched real- world single-center experienceSemantic proximity
Acute Myeloid Leukemia Patients With Myelodysplasia-Related Gene Mutations Benefit From Post-Transplant Hypomethylating Agent Maintenance.Semantic proximity
[Molecular Characteristics and Prognostic Analysis of Low-Risk Acute Myeloid Leukemia with Relapse].Semantic proximity
Smart Conditioning with Venetoclax Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid MalignanciesSemantic proximity
Select a neighboring publication to make it the new centre.